A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.
|Articles|February 15, 2022
- Pharm Exec E-Books-03-05-2021
- Volume Sponsored eBook
- Issue 1
Smarter Signal Management: AI, big data, and predictive analytics
Author(s)Oracle
What if you could predict potential safety issues before clinical development begins? Innovative new signal detection and management approaches have been developed to help clinical trial sponsors, manufacturers, and CROs combat safety-related challenges and provide insight to be used to predict potential safety issues even before clinical development begins. Applying those learnings to their choice of initial research candidates can ultimately mean safer medicines for patients.
Related to this article
Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds
Median net launch prices for new drugs climbed between 2022 and 2025 to $257,000, according to a new ICER and West Health report that also found persistent coverage and access barriers for patients.
The FDA approved GSK's bepirovirsen for adults with chronic hepatitis B on nucleoside therapy, based on phase 3 trials showing 19% functional cure.
Deborah Waterhouse is leaving ViiV Healthcare to become CEO and managing director of CSL.
Incubate’s John Stanford on why MFN’s first casualty is the moonshot — and why cancer, Alzheimer’s, and rare disease bear the cost.
METiS TechBio and Eli Lilly collaborate on next-generation LNP delivery technology, Incubate’s John Stanford on how MFN deals may shape future pharma decisions, and the FDA grants accelerated approval to GSK’s Jemperli for MSI-H/dMMR locally advanced rectal cancer.
METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.
Incubate’s John Stanford on why MFN reduces pharma’s appetite for biotech acquisitions — and why that cedes ground to China.
Trending on PharmExec
1
METiS Enters Collaboration with Eli Lilly for Next-Generation Tissue-Specific LNP Delivery Technologies
2
CSL Names Deborah Waterhouse as CEO and Manager Director
3
Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Jemperli
4
The Therapeutic Areas or Deals That Might Be Negatively Impacted by MFN Deals
5